Myriad Genetics (MYGN) EBIAT (2016 - 2025)
Historic EBIAT for Myriad Genetics (MYGN) over the last 17 years, with Q3 2025 value amounting to -$27.4 million.
- Myriad Genetics' EBIAT fell 2398.19% to -$27.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$400.5 million, marking a year-over-year decrease of 24525.86%. This contributed to the annual value of -$127.3 million for FY2024, which is 5165.21% up from last year.
- Latest data reveals that Myriad Genetics reported EBIAT of -$27.4 million as of Q3 2025, which was down 2398.19% from -$330.5 million recorded in Q2 2025.
- In the past 5 years, Myriad Genetics' EBIAT registered a high of $24.6 million during Q3 2021, and its lowest value of -$330.5 million during Q2 2025.
- Its 5-year average for EBIAT is -$46.7 million, with a median of -$31.2 million in 2023.
- In the last 5 years, Myriad Genetics' EBIAT skyrocketed by 26184.21% in 2021 and then tumbled by 80054.5% in 2025.
- Quarter analysis of 5 years shows Myriad Genetics' EBIAT stood at -$7.6 million in 2021, then plummeted by 456.58% to -$42.3 million in 2022, then grew by 26.24% to -$31.2 million in 2023, then crashed by 36.22% to -$42.5 million in 2024, then skyrocketed by 35.53% to -$27.4 million in 2025.
- Its last three reported values are -$27.4 million in Q3 2025, -$330.5 million for Q2 2025, and -$100000.0 during Q1 2025.